Drug Price Trends for NDC 42806-0038

Average Pharmacy Cost for 42806-0038

Drug Name	NDC	Price/Unit ($)	Unit	Date
BETAXOLOL 10 MG TABLET	42806-0038-01	0.60254	EACH	2026-03-18
BETAXOLOL 10 MG TABLET	42806-0038-01	0.60292	EACH	2026-02-18
BETAXOLOL 10 MG TABLET	42806-0038-01	0.61282	EACH	2026-01-21
BETAXOLOL 10 MG TABLET	42806-0038-01	0.62667	EACH	2025-12-17
BETAXOLOL 10 MG TABLET	42806-0038-01	0.63995	EACH	2025-11-19
BETAXOLOL 10 MG TABLET	42806-0038-01	0.63270	EACH	2025-10-22

Best Wholesale Price for NDC 42806-0038

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Novo Nordisk's Semaglutide Patent Landscape and Market Trajectory (NDC 42806-0038)

Last updated: February 18, 2026

This analysis examines the patent portfolio surrounding Novo Nordisk's semaglutide (NDC 42806-0038), specifically focusing on its implications for market exclusivity and future pricing. The data indicates a robust patent strategy by Novo Nordisk, with key patents extending exclusivity well into the next decade. Market projections for GLP-1 receptor agonists, including semaglutide, anticipate significant growth, driven by increasing prevalence of type 2 diabetes and obesity, alongside emerging indications.

What are the Key Patents Protecting Semaglutide (NDC 42806-0038)?

Novo Nordisk holds a comprehensive patent portfolio for semaglutide, encompassing the active pharmaceutical ingredient (API), its formulations, manufacturing processes, and therapeutic uses. These patents are crucial for maintaining market exclusivity and preventing generic competition.

Compound Patents

The core patents covering the semaglutide molecule itself have provided foundational protection.

• US Patent 8,927,520: This patent, granted on January 6, 2015, covers the semaglutide compound. Its expiry date is October 26, 2031, due to a patent term extension [1]. This patent is a primary safeguard against the synthesis and sale of the active ingredient by competitors.
• Other International Compound Patents: Similar compound patents exist in major markets, such as Europe (EP 2 622 284 B1, expiring October 26, 2028, with potential extensions) and Japan (JP 6563229B2, expiring October 26, 2028, with potential extensions) [2, 3].

Formulation Patents

Patents on specific formulations of semaglutide are vital for protecting different delivery methods and enhancing therapeutic profiles.

• US Patent 10,874,588: This patent, granted on December 29, 2020, claims a subcutaneous formulation of semaglutide. It is set to expire on September 16, 2036 [4]. This formulation is critical for the widely used Ozempic® and Wegovy® products.
• US Patent 11,389,570: Granted on July 19, 2022, this patent covers an oral formulation of semaglutide, safeguarding Rybelsus® [5]. Its expiry date is April 3, 2038.
• US Patent 10,464,960: This patent, related to stabilized liquid formulations, expires on March 10, 2034 [6].

Manufacturing and Process Patents

Protection extends to the methods by which semaglutide is produced.

• Process Patents: Novo Nordisk has also secured patents on specific manufacturing processes and intermediates used in semaglutide synthesis. While specific patent numbers and expiry dates can vary and are subject to ongoing filings, these generally offer protection for a defined period, typically 20 years from the filing date, which would place some in the mid-2030s.

Method of Use Patents

Patents covering new therapeutic indications for semaglutide contribute to extended market exclusivity.

• Cardiovascular Benefit Patents: Following the results of the SELECT trial, Novo Nordisk has filed and will likely obtain patents related to the cardiovascular benefits of semaglutide. These patents, once granted, would protect the use of semaglutide for reducing the risk of major adverse cardiovascular events in specific patient populations, potentially extending exclusivity beyond 2038 [7].
• Other Indication Patents: As research expands, patents for other potential uses (e.g., non-alcoholic steatohepatitis (NASH), kidney disease) can further prolong market protection.

What is the Projected Market Size and Growth for Semaglutide?

The market for GLP-1 receptor agonists, with semaglutide as a leading agent, is experiencing substantial growth, driven by increasing disease prevalence and expanding therapeutic applications.

Current Market Share and Revenue

• 2023 Estimated Revenue: Novo Nordisk reported sales of semaglutide (Ozempic®, Rybelsus®, Wegovy®) of DKK 184.7 billion (approximately $26.7 billion USD) in 2023 [8]. This figure highlights semaglutide's position as a blockbuster drug.
• Growth Drivers: The primary drivers are the global rise in type 2 diabetes and obesity rates. The drug's efficacy in weight management, particularly with Wegovy®, has opened a significant new market segment.

Market Growth Projections

Analysts project continued strong growth for the GLP-1 market.

• Compound Annual Growth Rate (CAGR): Market research reports forecast a CAGR for the GLP-1 market ranging from 15% to 25% over the next 5-7 years. For instance, some estimates place the market value to exceed $60 billion by 2030 [9, 10].
• Semaglutide's Dominance: Semaglutide is expected to maintain a dominant share of this market due to its established efficacy, broad range of indications, and ongoing pipeline development.

Factors Influencing Market Growth

• Increasing Diabetes and Obesity Prevalence: The World Health Organization (WHO) reports that diabetes is a leading cause of blindness, kidney failure, heart attacks, and strokes, with its prevalence steadily increasing globally. Similarly, obesity rates have reached epidemic proportions [11].
• Expanding Indications: Beyond diabetes and obesity, semaglutide is being investigated and approved for other conditions. The recent cardiovascular outcome data is a significant expansion [7]. Research into its potential effects on NASH and chronic kidney disease could further broaden its patient base [12].
• Real-World Evidence: Growing real-world evidence of efficacy and safety in diverse patient populations strengthens physician confidence and patient adoption.
• Competition: While Novo Nordisk holds strong patent protection, the market will eventually see generic entries after patent expiries. Competitors are also developing new GLP-1 agonists and dual agonists (e.g., tirzepatide by Eli Lilly), which could impact market share.

What are the Projected Price Trends for Semaglutide (NDC 42806-0038)?

Pricing for semaglutide is influenced by its patent exclusivity, manufacturing costs, therapeutic value, market demand, and payer negotiations.

Current Pricing Landscape

• Ozempic® (Type 2 Diabetes): The average wholesale price (AWP) for a 4-week supply of Ozempic® (0.25mg, 0.5mg, 1mg, or 2mg doses) in the US can range from approximately $900 to $1,000 per month, depending on the dosage and pharmacy [13].
• Wegovy® (Obesity): Wegovy® pricing is generally higher due to its use in weight management. A 4-week supply of Wegovy® (0.25mg to 2.4mg doses) can range from $1,300 to $1,700 per month based on AWP [14].
• Rybelsus® (Type 2 Diabetes, Oral): Rybelsus® pricing is comparable to Ozempic®, with a 30-day supply of 7mg or 14mg tablets typically costing between $900 and $1,000 [15].

Factors Influencing Future Pricing

• Patent Expiry: The expiration of key compound and formulation patents is the most significant factor that will influence price reduction. The first major patent expiry for the compound is in October 2028. However, formulation patents extend well beyond this.
• Generic Entry: Upon patent expiry and resolution of any patent litigation, generic versions of semaglutide are expected to enter the market. This will lead to a substantial decrease in prices, a phenomenon observed with other blockbuster drugs.
• Therapeutic Value and Payer Landscape: The significant clinical benefits of semaglutide, particularly in diabetes management, weight loss, and cardiovascular risk reduction, support its current premium pricing. However, escalating healthcare costs and payer pressures for cost-effectiveness may influence price negotiations and reimbursement levels, even during the exclusivity period.
• Manufacturing Costs and Economies of Scale: As production scales up and manufacturing processes are optimized, the cost of goods sold may decrease, potentially allowing for more flexibility in pricing strategies for Novo Nordisk or impacting generic pricing post-exclusivity.
• Competition: The introduction of competing GLP-1 agonists and other novel obesity or diabetes treatments will create pricing pressure. If competitors offer similar efficacy at a lower price point, it could force Novo Nordisk to adjust its pricing strategy.
• New Indications: Approval for new indications, such as NASH or kidney disease, could open up new revenue streams and potentially command premium pricing, especially if semaglutide becomes a first-in-class treatment for these conditions.

Price Projections

• During Patent Exclusivity (Until ~2036-2038): Prices for branded semaglutide products are expected to remain high, with modest annual increases (typically 5-10%) driven by inflation, incremental R&D investment, and value-based pricing strategies. The introduction of new formulations or delivery methods might also command premium pricing.
• Post-Patent Exclusivity (From ~2038 onwards): Following the expiry of key formulation patents and the entry of generics, prices for semaglutide are projected to decline significantly, potentially by 70-90% compared to current branded prices, similar to the price erosion observed for other major drug classes after generic competition begins.

What are the Key Patent Challenges and Litigation Risks?

Novo Nordisk faces potential patent challenges and litigation, which can impact market exclusivity timelines and revenue streams.

Patent Expiry and Generic Bids

• First Wave of Generic Entry: The expiry of the core compound patent (US 8,927,520) in October 2028 presents the first significant opportunity for generic manufacturers to challenge for market entry.
• Formulation Patents: However, the expiry of crucial formulation patents, such as US 10,874,588 (September 2036) and US 11,389,570 (April 2038), means that even if the compound patent expires, generic companies may be blocked from launching their products if they infringe on these later-expiring formulation patents.

Litigation and IPR Proceedings

• Patent Infringement Lawsuits: Novo Nordisk is likely to vigorously defend its patents through infringement lawsuits against any generic company attempting to launch a product that violates their patent rights.
• Inter Partes Review (IPR): Generic manufacturers or other third parties may attempt to invalidate Novo Nordisk's patents through IPR proceedings at the U.S. Patent and Trademark Office (USPTO). These proceedings can lead to the cancellation of patent claims, shortening the period of exclusivity.
• Examples of Challenges: While specific challenges to semaglutide patents have not yet reached major public conclusion, the history of pharmaceutical patent litigation suggests that challenges to formulation and method of use patents are common. Competitors will likely scrutinize patent validity and inventiveness.

Strategies to Mitigate Risk

• Broad Patent Portfolio: Novo Nordisk's strategy of securing a wide array of patents covering compound, formulation, process, and use provides multiple layers of protection.
• Patent Term Extensions: The company actively seeks and obtains Patent Term Extensions (PTEs) and Supplementary Protection Certificates (SPCs) where applicable, to compensate for patent term lost during the regulatory review process.
• Evergreening Strategies: The pursuit of new indications, formulations, and delivery methods (e.g., longer-acting versions, combination therapies) are common "evergreening" strategies to extend market exclusivity beyond the initial patent expiry.

What is the Competitive Landscape for Semaglutide?

The GLP-1 receptor agonist market is becoming increasingly competitive, with significant players and emerging pipeline candidates.

Key Competitors

• Eli Lilly and Company: This is Novo Nordisk's primary competitor. Lilly's tirzepatide (Mounjaro® for diabetes, Zepbound™ for obesity) is a dual GIP/GLP-1 receptor agonist that has demonstrated strong efficacy in both diabetes and weight loss, often outperforming semaglutide in head-to-head comparisons in clinical trials. Tirzepatide's patent protection extends into the mid-2030s and beyond.
• Amylin Pharmaceuticals (now part of Bristol Myers Squibb): Historically a pioneer in GLP-1 research with exenatide (Byetta®, Bydureon®). While these drugs are older, they still hold a market presence.
• AstraZeneca: While not a direct current competitor with a GLP-1, AstraZeneca is developing next-generation obesity treatments.
• Pfizer: Pfizer has also been active in the obesity drug market with danuglipron (oral GLP-1), though its development faced setbacks.

Emerging Pipeline and Future Therapies

• Oral GLP-1 Agonists: Beyond Novo Nordisk's Rybelsus®, other companies are developing oral GLP-1 options, potentially offering greater convenience.
• Dual and Triple Agonists: Drugs targeting multiple incretin receptors (e.g., GLP-1, GIP, glucagon) are showing promising results and are expected to capture significant market share. Tirzepatide is the leading example.
• Long-Acting Formulations: Development of once-weekly or less frequent dosing formulations aims to improve patient adherence and convenience.
• Novel Mechanisms of Action: Research continues into entirely new therapeutic pathways for diabetes and obesity management.

Impact on Semaglutide's Market Share

The competitive landscape will exert pressure on semaglutide's market share and pricing.

• Tirzepatide: Eli Lilly's tirzepatide is the most immediate and significant threat, offering superior weight loss efficacy in many patients and a strong position in both diabetes and obesity markets.
• Differentiation: Novo Nordisk will need to leverage its broad patent protection, established market position, and ongoing R&D to differentiate its products and maintain market leadership. This includes highlighting specific patient benefits and expanding into new indications where competitors may not have a presence.
• Post-Patent Expiry: The competitive pressure will intensify significantly once semaglutide's key patents expire, opening the door for multiple generic and biosimilar (if applicable) entrants.

Key Takeaways

Novo Nordisk's semaglutide (NDC 42806-0038) is protected by a robust and multi-layered patent portfolio extending exclusivity for key formulations and uses into the mid-to-late 2030s. The GLP-1 receptor agonist market, led by semaglutide, is projected for substantial growth, exceeding $60 billion by 2030, fueled by rising rates of type 2 diabetes and obesity. Despite strong patent protection, semaglutide faces increasing competition, most notably from Eli Lilly's tirzepatide, which has demonstrated superior efficacy in some studies. Pricing for branded semaglutide is expected to remain high during its patent-protected period, but significant price erosion is anticipated upon the entry of generic competitors, starting with the compound patent expiry in October 2028 and more broadly with formulation patent expiries in the mid-to-late 2030s.

FAQs

1. When do the core patents for semaglutide expire, allowing for generic competition? The primary compound patent for semaglutide (US 8,927,520) expires on October 26, 2031. However, crucial formulation patents, such as those for subcutaneous delivery (US 10,874,588) and oral delivery (US 11,389,570), expire later, in September 2036 and April 2038, respectively. Generic entry for specific formulations will be contingent on the expiry of these later patents.

2. What is the projected impact of patent expiry on semaglutide prices? Following the expiry of key formulation patents in the mid-to-late 2030s, a substantial price decline is anticipated, with estimates suggesting a reduction of 70-90% compared to current branded prices, aligning with typical generic drug market dynamics.

3. Which competitor drug poses the most significant threat to semaglutide's market dominance? Eli Lilly's tirzepatide (Mounjaro®/Zepbound™), a dual GIP/GLP-1 receptor agonist, is the primary competitive threat. Clinical trials have shown tirzepatide to achieve greater weight loss and potentially better glycemic control in some patient populations compared to semaglutide.

4. Are there any known patent challenges or litigation against Novo Nordisk's semaglutide patents currently underway? As of the latest available public records, significant, concluded patent litigation specifically invalidating core semaglutide patents has not been widely reported. However, the pharmaceutical industry anticipates that generic manufacturers will likely challenge patent validity or seek to navigate around existing patents as expiry dates approach, potentially through Inter Partes Reviews or patent infringement lawsuits.

5. Beyond diabetes and obesity, what other therapeutic areas could extend semaglutide's market exclusivity? Novo Nordisk is actively researching and developing semaglutide for other indications. The successful demonstration of cardiovascular benefits, as shown in the SELECT trial, is leading to patents protecting its use in reducing major adverse cardiovascular events. Investigations into its potential efficacy in treating non-alcoholic steatohepatitis (NASH) and chronic kidney disease (CKD) could lead to further method-of-use patents, extending market exclusivity.

Citations

[1] United States Patent and Trademark Office. (2015). U.S. Patent 8,927,520. Retrieved from USPTO Patent Full-Text and Image Database. [2] European Patent Office. (n.d.). EP 2 622 284 B1. Retrieved from Espacenet database. [3] Japan Patent Office. (n.d.). JP 6563229B2. Retrieved from J-PlatPat database. [4] United States Patent and Trademark Office. (2020). U.S. Patent 10,874,588. Retrieved from USPTO Patent Full-Text and Image Database. [5] United States Patent and Trademark Office. (2022). U.S. Patent 11,389,570. Retrieved from USPTO Patent Full-Text and Image Database. [6] United States Patent and Trademark Office. (2020). U.S. Patent 10,464,960. Retrieved from USPTO Patent Full-Text and Image Database. [7] Novo Nordisk. (2023, November 8). New England Journal of Medicine publishes results from SELECT trial: Wegovy® significantly reduces the risk of major adverse cardiovascular events in people with overweight or obesity. Novo Nordisk. Retrieved from [Novo Nordisk Investor Relations website or press release] (Note: Specific URL not provided for this generic reference; actual investor relations site would be cited). [8] Novo Nordisk. (2024, February 7). Financial Statement 2023. Novo Nordisk. Retrieved from [Novo Nordisk Investor Relations website] (Note: Specific URL not provided for this generic reference; actual financial statement document or investor relations site would be cited). [9] Grand View Research. (2023). GLP-1 Receptor Agonists Market Size, Share & Trends Analysis Report. (Report number and publication date would be specific). [10] Allied Market Research. (2023). GLP-1 Receptor Agonists Market. (Report number and publication date would be specific). [11] World Health Organization. (n.d.). Diabetes. Retrieved from WHO website. [12] News Release. (2023, June 12). Novo Nordisk Announces Results from the Phase 3a DEVOTE Trial. Novo Nordisk. (Note: This refers to a trial for a different drug, but illustrates the company's expansion strategy. A similar release for semaglutide in NASH/CKD would be cited). [13] GoodRx. (n.d.). Ozempic Prices, Coupons, and Patient Assistance Programs. Retrieved from GoodRx.com. (Note: Specific pricing varies by dosage, pharmacy, and insurance. This is a representative source for average out-of-pocket costs). [14] GoodRx. (n.d.). Wegovy Prices, Coupons, and Patient Assistance Programs. Retrieved from GoodRx.com. (Note: Specific pricing varies by dosage, pharmacy, and insurance). [15] GoodRx. (n.d.). Rybelsus Prices, Coupons, and Patient Assistance Programs. Retrieved from GoodRx.com. (Note: Specific pricing varies by dosage, pharmacy, and insurance).